『IFM | New Oral Medication to Prevent COVID-19 After Exposure』のカバーアート

IFM | New Oral Medication to Prevent COVID-19 After Exposure

IFM | New Oral Medication to Prevent COVID-19 After Exposure

無料で聴く

ポッドキャストの詳細を見る

【Amazonプライム会員限定】今ならプレミアムプランが4か月 月額99円。

10月19日まで。※適用条件あり
In this special sponsored episode of the Inside Family Medicine podcast, brought to you by Shionogi, host Darren Sextro talks with family physician Ben Silverberg, MD, about ensitrelvir, a newly approved oral medication for COVID-19 post-exposure prophylaxis (PEP). Dr. Silverberg explains how the medication works to inhibit viral replication and discusses findings from the Phase III SCORPIO-PEP trial, which evaluated ensitrelvir among household contacts of people with confirmed COVID-19. The conversation highlights the importance of starting post-exposure prophylaxis quickly, along with safety considerations, potential drug interactions and factors family physicians may evaluate when determining whether a patient may be eligible. The discussion also explores how this new option may fit alongside vaccination and other COVID-19 prevention strategies, particularly during respiratory illness season. Dr. Silverberg discusses patients who may benefit from a conversation about PEP after a known exposure, including older adults, people with chronic conditions, individuals who are not up to date on vaccination and those who may face significant challenges if they become ill. Throughout the episode, he emphasizes the role family physicians can play in helping patients understand their options and navigate COVID-19 prevention as the virus continues to evolve. References and resources Ensitrelvir for Covid-19 Postexposure Prophylaxis in Household Contacts — New England Journal of Medicine Shionogi Announces FDA Approval of XOCOVA® (ensitrelvir), the First and Only Oral Option to Help Prevent COVID-19 Following Exposure AAFP resources related to COVID-19 prevention Immunizations And Vaccines For Family Physicians | AAFP COVID-19 antiviral treatment | Family Doctor Topics by timestamp 00:00 Introduction 01:27 A new option for COVID-19 post-exposure prevention 01:58 What is ensitrelvir and how does it work? 03:21 Preventing COVID-19 spread within households 03:46 Clinical considerations for family physicians 04:03 Inside the SCORPIO-PEP trial 05:00 Effectiveness and importance of early treatment 05:29 Safety profile and adverse events 06:12 Which patients may be appropriate candidates? 07:00 Patients who may benefit during respiratory season 07:23 Key takeaways for talking with patients 07:43 Vaccination and post-exposure prophylaxis 08:18 Closing thoughts and COVID-19 resources This episode is brought to you by Shionogi. Disclaimer: Copyright 2026. AAFP. The views presented in this broadcast are the speaker's own and do not represent those of AAFP. The information presented is for general, educational, or entertainment purposes and should not be considered legal, health, financial, or other advice.  AAFP makes no representation as to the accuracy or completeness of the information and is not responsible for results that may arise from its use.  Consult an appropriate professional concerning your specific situation and respective governing bodies for applicable laws. Reference to any specific product or entity does not constitute an endorsement or recommendation by AAFP unless specifically stated otherwise.  AAFP and the AAFP logo are registered trademarks of American Academy of Family Physicians.
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません